{"id":32872,"date":"2022-12-06T11:12:11","date_gmt":"2022-12-06T10:12:11","guid":{"rendered":"https:\/\/www.silvereco.org\/en\/?p=32872"},"modified":"2026-01-22T13:48:52","modified_gmt":"2026-01-22T12:48:52","slug":"light4life-a-pivotal-clinical-study-by-regenlife-to-evaluate-the-therapeutic-efficacy-of-its-photomedical-technology-in-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.silvereco.org\/en\/light4life-a-pivotal-clinical-study-by-regenlife-to-evaluate-the-therapeutic-efficacy-of-its-photomedical-technology-in-alzheimers-disease\/","title":{"rendered":"Light4life : a pivotal clinical study by REGEnLIFE to evaluate the therapeutic efficacy of its photomedical technology in Alzheimer’s disease"},"content":{"rendered":"\n

During the 15th edition of the CTAD (Clinical Trials on Alzheimer’s Disease) taking place from November 29 to December 2 of 2022 in San Francisco, USA, REGEnLIFE, a French company specialized in the research and development of innovative technologies in photo-medicine for the prevention and treatment of neurodegenerative diseases, presented the concept of its next clinical study, Light4life.<\/p>\n\n\n\n\n\n\n\n

\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Dementia : new cases every 3.2 seconds worldwide<\/h2>\n\n\n\n

This pivotal study, which will be conducted in France in 2023 on 108 patients with Alzheimer’s disease, is designed to evaluate the cognitive impact of PhotoBioModulation (PBM)<\/strong>, an innovative non-invasive therapy that acts on inflammation in the brain-gut axis, which is believed to be responsible for the development of Alzheimer’s disease and other neurodegenerative diseases. In 2020, more than 55 million people worldwide suffered from dementia.<\/strong> This number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050. Currently, there is no treatment to cure this disease.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\n

Based on these encouraging study results published in November in the Journal of Alzheimer’s Disease, REGEnLIFE will organize a multicenter pivotal study that will begin in early 2023 at the Toulouse University Hospital’s Gerontopole, directed by Professor Bruno VELLAS. 108 patients with mild to moderate Alzheimer’s disease will be treated for six months and followed for one year. […] We are taking advantage of our presence at CTAD to present this study project to our peers. We are very hopeful that this new study will provide another form of non-drug, non-invasive management for a disease for which we still do not have an effective treatment.“<\/strong><\/em><\/p>\nProfessor Jacques TOUCHON, Neurologist, Scientific Advisor of REGEnLIFE and Co-Founder of CTAD<\/cite><\/blockquote>\n\n\n\n

\n
5 Tips for Alzheimer’s care at Christmas<\/a><\/blockquote>